AstraZeneca (AZN) Revenue & Revenue Breakdown
AstraZeneca Revenue Highlights
Latest Revenue (Y)
$45.81B
Latest Revenue (Q)
$12.68B
Main Segment (Y)
Total Oncology
Main Geography (Y)
The Americas
AstraZeneca Revenue by Period
AstraZeneca Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $45.81B | 3.29% |
2022-12-31 | $44.35B | 18.53% |
2021-12-31 | $37.42B | 40.58% |
2020-12-31 | $26.62B | 9.16% |
2019-12-31 | $24.38B | 10.38% |
2018-12-31 | $22.09B | -1.67% |
2017-12-31 | $22.46B | -2.33% |
2016-12-31 | $23.00B | -6.90% |
2015-12-31 | $24.71B | -5.32% |
2014-12-31 | $26.09B | 1.49% |
2013-12-31 | $25.71B | -8.09% |
2012-12-31 | $27.97B | -16.72% |
2011-12-31 | $33.59B | 0.97% |
2010-12-31 | $33.27B | 1.42% |
2009-12-31 | $32.80B | 3.81% |
2008-12-31 | $31.60B | 6.91% |
2007-12-31 | $29.56B | 11.65% |
2006-12-31 | $26.48B | 10.54% |
2005-12-31 | $23.95B | 11.78% |
2004-12-31 | $21.43B | 13.67% |
2003-12-31 | $18.85B | 5.60% |
2002-12-31 | $17.85B | -24.27% |
2001-12-31 | $23.57B | 30.11% |
2000-12-31 | $18.12B | -1.74% |
1999-12-31 | $18.44B | 101.57% |
1998-12-31 | $9.15B | 6.52% |
1997-12-31 | $8.59B | -6.51% |
1996-12-31 | $9.18B | 21.35% |
1995-12-31 | $7.57B | 8.06% |
1994-12-31 | $7.00B | 6.64% |
1993-12-31 | $6.57B | - |
AstraZeneca generated $45.81B in revenue during NA 2023, up 3.29% compared to the previous quarter, and up 207.38% compared to the same period a year ago.
AstraZeneca Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $12.68B | 5.45% |
2023-12-31 | $12.02B | 4.63% |
2023-09-30 | $11.49B | 0.67% |
2023-06-30 | $11.42B | 4.94% |
2023-03-31 | $10.88B | -2.93% |
2022-12-31 | $11.21B | 2.05% |
2022-09-30 | $10.98B | 1.96% |
2022-06-30 | $10.77B | -5.43% |
2022-03-31 | $11.39B | -5.17% |
2021-12-31 | $12.01B | 21.74% |
2021-09-30 | $9.87B | 20.02% |
2021-06-30 | $8.22B | 12.30% |
2021-03-31 | $7.32B | -1.21% |
2020-12-31 | $7.41B | 12.65% |
2020-09-30 | $6.58B | 4.83% |
2020-06-30 | $6.28B | -1.24% |
2020-03-31 | $6.35B | -4.65% |
2019-12-31 | $6.66B | 4.03% |
2019-09-30 | $6.41B | 10.01% |
2019-06-30 | $5.82B | 6.05% |
2019-03-31 | $5.49B | -14.43% |
2018-12-31 | $6.42B | 20.17% |
2018-09-30 | $5.34B | 3.59% |
2018-06-30 | $5.16B | -0.44% |
2018-03-31 | $5.18B | -10.37% |
2017-12-31 | $5.78B | -7.30% |
2017-09-30 | $6.23B | 23.38% |
2017-06-30 | $5.05B | -6.55% |
2017-03-31 | $5.41B | -3.22% |
2016-12-31 | $5.58B | -2.00% |
2016-09-30 | $5.70B | 1.71% |
2016-06-30 | $5.60B | -8.37% |
2016-03-31 | $6.12B | -4.44% |
2015-12-31 | $6.40B | 7.64% |
2015-09-30 | $5.95B | -5.74% |
2015-06-30 | $6.31B | 4.13% |
2015-03-31 | $6.06B | -9.37% |
2014-12-31 | $6.68B | 2.16% |
2014-09-30 | $6.54B | 1.36% |
2014-06-30 | $6.45B | 0.59% |
2014-03-31 | $6.42B | -6.25% |
2013-12-31 | $6.84B | 9.50% |
2013-09-30 | $6.25B | 0.29% |
2013-06-30 | $6.23B | -2.40% |
2013-03-31 | $6.38B | -12.32% |
2012-12-31 | $7.28B | 8.98% |
2012-09-30 | $6.68B | 0.33% |
2012-06-30 | $6.66B | -9.38% |
2012-03-31 | $7.35B | -15.10% |
2011-12-31 | $8.66B | 5.39% |
2011-09-30 | $8.21B | -2.57% |
2011-06-30 | $8.43B | 1.66% |
2011-03-31 | $8.29B | -3.77% |
2010-12-31 | $8.62B | 9.10% |
2010-09-30 | $7.90B | -3.42% |
2010-06-30 | $8.18B | -4.64% |
2010-03-31 | $8.58B | -4.13% |
2009-12-31 | $8.95B | 9.09% |
2009-09-30 | $8.20B | 3.04% |
2009-06-30 | $7.96B | 3.34% |
2009-03-31 | $7.70B | -6.01% |
2008-12-31 | $8.19B | 5.38% |
2008-09-30 | $7.78B | -2.28% |
2008-06-30 | $7.96B | 3.63% |
2008-03-31 | $7.68B | -6.03% |
2007-12-31 | $8.17B | 14.27% |
2007-09-30 | $7.15B | - |
AstraZeneca generated $12.68B in revenue during Q1 2024, up 5.45% compared to the previous quarter, and up 113.13% compared to the same period a year ago.
AstraZeneca Revenue Breakdown
AstraZeneca Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Pulmicort | $713.00M | $645.00M | $1.47B | - | - |
Roxadustat | $271.00M | $197.00M | $174.00M | - | - |
Saphnelo | $280.00M | $116.00M | - | - | - |
Seloken/Toprol-XL | $640.00M | $862.00M | - | - | - |
Soliris | $3.15B | $3.76B | - | - | - |
Strensiq | $1.15B | $958.00M | - | - | - |
Andexxa | $182.00M | $150.00M | - | - | - |
Zoladex | $952.00M | $927.00M | $948.00M | $888.00M | $813.00M |
Vaxzevria | $12.00M | $1.80B | - | - | - |
Ultomiris. | $2.96B | $1.97B | - | - | - |
Total Other medicines | $1.18B | $1.63B | - | - | - |
Total Oncology | $17.14B | $14.63B | - | - | - |
Tagrisso | $5.80B | $5.44B | $3.19B | - | - |
Synagis | $546.00M | $578.00M | $358.00M | - | - |
Symbicort | $2.36B | $2.54B | $2.50B | - | - |
Enhertu | $1.02B | $79.00M | $17.00M | - | - |
Bevespi | $58.00M | $58.00M | $42.00M | - | - |
Breztri | $677.00M | $398.00M | $2.00M | - | - |
Brilinta | $1.32B | $1.36B | $1.58B | - | - |
Bydureon | $163.00M | $280.00M | $549.00M | - | - |
CVRM | $10.59B | $9.19B | - | - | - |
Calquence | $2.51B | $2.06B | $164.00M | - | - |
Crestor | $1.11B | $1.05B | $1.10B | $1.18B | $1.28B |
Daliresp/Daxas | $54.00M | $189.00M | - | - | - |
Farxiga | $5.96B | $4.38B | $1.54B | - | - |
Fasenra | $1.55B | $1.40B | $704.00M | - | - |
Faslodex | $297.00M | $334.00M | $892.00M | - | - |
FluMist | $216.00M | $175.00M | - | - | - |
Imfinzi | $4.24B | $2.78B | $1.47B | - | - |
Kanuma | $171.00M | $160.00M | - | - | - |
Koselugo | $331.00M | $208.00M | - | - | - |
Lokelma | $412.00M | $289.00M | $14.00M | - | - |
Lynparza | $2.81B | $2.64B | $1.20B | - | - |
Nexium | $945.00M | $1.28B | $1.33B | $1.48B | - |
Oncology, Others | $224.00M | $44.00M | - | - | - |
Onglyza | $227.00M | $257.00M | $527.00M | - | - |
Other, Others | $231.00M | $340.00M | - | - | - |
Rare Disease | $7.76B | $7.05B | - | - | - |
Ophatys | - | $33.00M | - | - | - |
Iressa | - | $114.00M | $423.00M | - | - |
Casodex | - | $78.00M | $200.00M | - | - |
BioPharmaceuticals: total Respiratory & Immunology | - | $5.76B | - | - | - |
Arimidex | - | $99.00M | $225.00M | - | - |
Respiratory, Others | - | $421.00M | - | - | - |
Other Ongoing Collaboration Revenue | - | - | $64.00M | - | - |
Lynparza/Koselugo | - | - | $400.00M | - | - |
Royal income | - | - | $138.00M | - | - |
Profit share revenue from product sales by collaboration partners | - | - | $200.00M | - | - |
Collaboration Revenue | - | - | $12.00M | - | - |
Royal Revenue | - | - | - | $62.00M | - |
Other Collaboration Revenue | - | - | - | $46.00M | - |
Lynparza And Koselugo | - | - | - | $460.00M | - |
Seroquel Xr Ir | - | - | - | - | $191.00M |
Seloken Toprol Xl | - | - | - | - | $760.00M |
Respiratory Products | - | - | - | - | $5.39B |
Other Respiratory Products | - | - | - | - | $390.00M |
Other Products | - | - | - | - | $2.60B |
Other Products Others | - | - | - | - | $306.00M |
Other Oncology Products | - | - | - | - | $94.00M |
Other Diabetes | - | - | - | - | $52.00M |
Other Cardiovascular And Metabolic Diseases Products | - | - | - | - | $271.00M |
Oncology Products | - | - | - | - | $8.67B |
Losec Prilosec | - | - | - | - | $263.00M |
Duaklir | - | - | - | - | $77.00M |
Daliresp Daxas | - | - | - | - | $215.00M |
Cardiovascular And Metabolic Diseases Products | - | - | - | - | $6.91B |
Byetta | - | - | - | - | $110.00M |
Atacand | - | - | - | - | $221.00M |
AstraZeneca's latest annual revenue breakdown by segment (product or service), as of Dec 23: Total Oncology (21.37%), CVRM (13.19%), Rare Disease (9.68%), Farxiga (7.43%), Tagrisso (7.23%), Imfinzi (5.28%), Soliris (3.92%), Ultomiris. (3.70%), Lynparza (3.50%), Calquence (3.13%), Symbicort (2.94%), Fasenra (1.94%), Brilinta (1.65%), Total Other medicines (1.47%), Strensiq (1.44%), Crestor (1.38%), Enhertu (1.27%), Zoladex (1.19%), Nexium (1.18%), Pulmicort (0.89%), Breztri (0.84%), Seloken/Toprol-XL (0.80%), Synagis (0.68%), Lokelma (0.51%), Koselugo (0.41%), Faslodex (0.37%), Saphnelo (0.35%), Roxadustat (0.34%), Other, Others (0.29%), Onglyza (0.28%), Oncology, Others (0.28%), FluMist (0.27%), Andexxa (0.23%), Kanuma (0.21%), Bydureon (0.20%), Bevespi (0.07%), Daliresp/Daxas (0.07%), and Vaxzevria (0.01%).
Quarterly Revenue by Product
Product/Service | Dec 23 | Jun 23 | Jun 22 | Jun 21 | Jun 19 |
---|---|---|---|---|---|
Bevespi | $43.00M | $15.00M | $11.00M | $13.00M | $20.00M |
Tagrisso | $4.31B | $1.49B | $513.00M | $1.31B | $784.00M |
Synagis | $459.00M | $87.00M | $2.00M | $24.00M | $96.00M |
Symbicort | $1.76B | $600.00M | $222.00M | $680.00M | $585.00M |
Strensiq | $852.00M | $300.00M | $193.00M | - | - |
Roxadustat | $198.00M | $73.00M | $50.00M | $51.00M | - |
Soliris | $2.33B | $814.00M | $574.00M | - | - |
Seloken/Toprol-XL | $476.00M | $164.00M | $223.00M | - | - |
Pulmicort | $589.00M | $124.00M | $15.00M | $167.00M | $333.00M |
Saphnelo | $212.00M | $68.00M | $23.00M | - | - |
Andexxa | $137.00M | $45.00M | $18.00M | - | - |
Zoladex | $719.00M | $233.00M | $3.00M | $244.00M | $197.00M |
Vaxzevria | - | $28.00M | - | - | - |
Total Other medicines | $875.00M | $301.00M | $36.00M | - | - |
Total Oncology | $12.76B | $4.38B | $1.60B | - | - |
Other, Others | $178.00M | $53.00M | $6.00M | - | - |
Onglyza | $162.00M | $65.00M | $22.00M | $99.00M | $116.00M |
Oncology, Others | $170.00M | $54.00M | $1.00M | - | - |
Nexium | $697.00M | $248.00M | $30.00M | $336.00M | $393.00M |
Lynparza | $2.09B | $717.00M | $312.00M | $588.00M | $283.00M |
Lokelma | $312.00M | $100.00M | $39.00M | $39.00M | - |
Koselugo | $251.00M | $80.00M | $47.00M | $1.00M | - |
Kanuma | $125.00M | $46.00M | $20.00M | - | - |
Imfinzi | $3.16B | $1.08B | $374.00M | $604.00M | $338.00M |
FluMist | $213.00M | $3.00M | $1.00M | - | - |
Faslodex | $219.00M | $78.00M | $5.00M | $105.00M | $267.00M |
Fasenra | $1.15B | $406.00M | $230.00M | $320.00M | $167.00M |
Farxiga | $4.46B | $1.50B | $275.00M | $732.00M | $377.00M |
Daliresp/Daxas | $37.00M | $17.00M | $54.00M | - | - |
Calquence | $1.86B | $653.00M | $396.00M | $280.00M | $64.00M |
Bydureon | $120.00M | $43.00M | $62.00M | $95.00M | $141.00M |
Brilinta | $993.00M | $331.00M | $185.00M | $375.00M | $389.00M |
Breztri | $514.00M | $163.00M | $53.00M | $56.00M | - |
Enhertu | $955.00M | $67.00M | $18.00M | $3.00M | - |
Respiratory, Others | - | $71.00M | $46.00M | - | - |
BioPharmaceuticals: total Respiratory & Immunology | - | $1.48B | $654.00M | - | - |
Ultomiris | - | $713.00M | $236.00M | - | - |
Crestor. | - | $280.00M | $16.00M | - | - |
Arimidex | - | - | $28.00M | $29.00M | $60.00M |
Casodex | - | - | $21.00M | $41.00M | $57.00M |
Iressa | - | - | $2.00M | $47.00M | $118.00M |
Byetta | - | - | - | $16.00M | $25.00M |
Atacand | - | - | - | $23.00M | $56.00M |
Cardiovascular Renal And Metabolism Products | - | - | - | $2.02B | $1.66B |
Covid19 Vaccine Astrazeneca C19vaz | - | - | - | $862.00M | - |
Covid19 | - | - | - | $862.00M | - |
Crestor | - | - | - | $265.00M | $310.00M |
Daliresp Daxas | - | - | - | $54.00M | $56.00M |
Flumist | - | - | - | $2.00M | - |
Losec Prilosec | - | - | - | $46.00M | $68.00M |
Oncology Products | - | - | - | $3.29B | $2.17B |
Other Cardiovascular Renal And Metabolism Products | - | - | - | $47.00M | $68.00M |
Other Diabetes | - | - | - | $15.00M | - |
Other Oncology Products | - | - | - | $13.00M | $28.00M |
Other Products Others | - | - | - | $26.00M | $30.00M |
Other Products | - | - | - | $454.00M | $641.00M |
Other Respiratory Products | - | - | - | $130.00M | $71.00M |
Respiratory Products | - | - | - | $1.42B | $1.25B |
Seloken Toprol Xl | - | - | - | $266.00M | $168.00M |
Seroquel Xr Ir | - | - | - | $21.00M | $32.00M |
Duaklir | - | - | - | - | $1.00M |
Symlin | - | - | - | - | $15.00M |
Movantik Moventig | - | - | - | - | $47.00M |
Tudorza Eklira | - | - | - | - | $13.00M |
AstraZeneca's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Total Oncology (29.41%), Farxiga (10.27%), Tagrisso (9.93%), Imfinzi (7.28%), Soliris (5.37%), Lynparza (4.83%), Calquence (4.29%), Symbicort (4.06%), Fasenra (2.64%), Brilinta (2.29%), Enhertu (2.20%), Total Other medicines (2.02%), Strensiq (1.96%), Zoladex (1.66%), Nexium (1.61%), Pulmicort (1.36%), Breztri (1.18%), Seloken/Toprol-XL (1.10%), Synagis (1.06%), Lokelma (0.72%), Koselugo (0.58%), Faslodex (0.50%), FluMist (0.49%), Saphnelo (0.49%), Roxadustat (0.46%), Other, Others (0.41%), Oncology, Others (0.39%), Onglyza (0.37%), Andexxa (0.32%), Kanuma (0.29%), Bydureon (0.28%), Bevespi (0.10%), and Daliresp/Daxas (0.09%).
AstraZeneca Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Europe | $9.72B | $8.91B | $6.79B | - | - |
Japan | $3.64B | $3.99B | - | - | - |
Italy | $813.00M | $735.00M | - | - | - |
France | $1.15B | $1.11B | - | - | - |
Spain | $847.00M | $738.00M | - | - | - |
Sweden | $1.70B | $1.72B | - | - | - |
The Americas | $20.77B | $20.13B | $14.89B | - | - |
UK | $3.37B | $996.00M | $1.21B | - | - |
Asia, Africa And Australasia | $11.95B | $14.37B | $13.65B | - | - |
Australia | $390.00M | $571.00M | - | - | - |
Canada | $967.00M | $1.17B | - | - | - |
China | $5.87B | $5.74B | - | - | - |
Other, Europe | $3.11B | $2.71B | - | - | - |
Europe excluding the United Kingdom | - | $7.50B | - | - | - |
Asia Africa And Australasia | - | - | - | $10.83B | $10.18B |
Ifrs Americas | - | - | - | $10.00B | $9.03B |
Ifrs Europe | - | - | - | $4.45B | $3.89B |
Ifrs Country Gb | - | - | - | $611.00M | $458.00M |
AstraZeneca's latest annual revenue breakdown by geography, as of Dec 23: The Americas (32.30%), Asia, Africa And Australasia (18.58%), Europe (15.12%), China (9.13%), Japan (5.66%), UK (5.24%), Other, Europe (4.84%), Sweden (2.65%), France (1.79%), Canada (1.50%), Spain (1.32%), Italy (1.26%), and Australia (0.61%).
Quarterly Revenue by Country
Country | Jun 21 |
---|---|
Ifrs Country Jp | $75.00M |
AstraZeneca's latest quarterly revenue breakdown by geography, as of Jun 21: Ifrs Country Jp (100.00%).
AstraZeneca Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
JNJ | Johnson & Johnson | $85.15B | $22.45B |
MRK | Merck | $60.12B | $16.11B |
PFE | Pfizer | $58.50B | $13.28B |
ABBV | AbbVie | $54.32B | $14.46B |
NVS | Novartis | $46.66B | $11.83B |
AZN | AstraZeneca | $45.81B | $12.68B |
BMY | Bristol-Myers Squibb | $45.01B | $12.20B |
SNY | Sanofi | $43.07B | $11.12B |
LLY | Eli Lilly and | $34.12B | $11.30B |
GSK | GSK | $30.33B | $7.36B |
AMGN | Amgen | $28.19B | $8.39B |
GILD | Gilead Sciences | $27.12B | $6.95B |
AZN Revenue FAQ
What is AstraZeneca’s yearly revenue?
AstraZeneca's yearly revenue for 2023 was $45.81B, representing an increase of 3.29% compared to 2022. The company's yearly revenue for 2022 was $44.35B, representing an increase of 18.53% compared to 2021. AZN's yearly revenue for 2021 was $37.42B, representing an increase of 40.58% compared to 2020.
What is AstraZeneca’s quarterly revenue?
AstraZeneca's quarterly revenue for Q1 2024 was $12.68B, a 5.45% increase from the previous quarter (Q4 2023), and a 16.55% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $12.02B, a 4.63% increase from the previous quarter (Q3 2023), and a 7.29% increase year-over-year (Q4 2022). AZN's quarterly revenue for Q3 2023 was $11.49B, a 0.67% increase from the previous quarter (Q2 2023), and a 4.64% increase year-over-year (Q3 2022).
What is AstraZeneca’s revenue growth rate?
AstraZeneca's revenue growth rate for the last 3 years (2021-2023) was 22.43%, and for the last 5 years (2019-2023) was 87.87%.
What are AstraZeneca’s revenue streams?
AstraZeneca's revenue streams in c 23 are Pulmicort, Roxadustat, Saphnelo, Seloken/Toprol-XL, Soliris, Strensiq, Andexxa, Zoladex, Vaxzevria, Ultomiris., Total Other medicines, Total Oncology, Tagrisso, Synagis, Symbicort, Enhertu, Bevespi, Breztri, Brilinta, Bydureon, CVRM, Calquence, Crestor, Daliresp/Daxas, Farxiga, Fasenra, Faslodex, FluMist, Imfinzi, Kanuma, Koselugo, Lokelma, Lynparza, Nexium, Oncology, Others, Onglyza, Other, Others, and Rare Disease. Pulmicort generated $713M in revenue, accounting 0.89% of the company's total revenue, up 10.54% year-over-year. Roxadustat generated $271M in revenue, accounting 0.34% of the company's total revenue, up 37.56% year-over-year. Saphnelo generated $280M in revenue, accounting 0.35% of the company's total revenue, up 141.38% year-over-year. Seloken/Toprol-XL generated $640M in revenue, accounting 0.80% of the company's total revenue, down -25.75% year-over-year. Soliris generated $3.14B in revenue, accounting 3.92% of the company's total revenue, down -16.40% year-over-year. Strensiq generated $1.15B in revenue, accounting 1.44% of the company's total revenue, up 20.25% year-over-year. Andexxa generated $182M in revenue, accounting 0.23% of the company's total revenue, up 21.33% year-over-year. Zoladex generated $952M in revenue, accounting 1.19% of the company's total revenue, up 2.70% year-over-year. Vaxzevria generated $12M in revenue, accounting 0.01% of the company's total revenue, down -99.33% year-over-year. Ultomiris. generated $2.96B in revenue, accounting 3.70% of the company's total revenue, up 50.89% year-over-year. Total Other medicines generated $1.18B in revenue, accounting 1.47% of the company's total revenue, down -27.63% year-over-year. Total Oncology generated $17.14B in revenue, accounting 21.37% of the company's total revenue, up 17.18% year-over-year. Tagrisso generated $5.8B in revenue, accounting 7.23% of the company's total revenue, up 6.52% year-over-year. Synagis generated $546M in revenue, accounting 0.68% of the company's total revenue, down -5.54% year-over-year. Symbicort generated $2.36B in revenue, accounting 2.94% of the company's total revenue, down -6.93% year-over-year. Enhertu generated $1.02B in revenue, accounting 1.27% of the company's total revenue, up 1193.67% year-over-year. Bevespi generated $58M in revenue, accounting 0.07% of the company's total revenue Breztri generated $677M in revenue, accounting 0.84% of the company's total revenue, up 70.10% year-over-year. Brilinta generated $1.32B in revenue, accounting 1.65% of the company's total revenue, down -2.50% year-over-year. Bydureon generated $163M in revenue, accounting 0.20% of the company's total revenue, down -41.79% year-over-year. CVRM generated $10.58B in revenue, accounting 13.19% of the company's total revenue, up 15.20% year-over-year. Calquence generated $2.51B in revenue, accounting 3.13% of the company's total revenue, up 22.22% year-over-year. Crestor generated $1.11B in revenue, accounting 1.38% of the company's total revenue, up 5.63% year-over-year. Daliresp/Daxas generated $54M in revenue, accounting 0.07% of the company's total revenue, down -71.43% year-over-year. Farxiga generated $5.96B in revenue, accounting 7.43% of the company's total revenue, up 36.11% year-over-year. Fasenra generated $1.55B in revenue, accounting 1.94% of the company's total revenue, up 11.25% year-over-year. Faslodex generated $297M in revenue, accounting 0.37% of the company's total revenue, down -11.08% year-over-year. FluMist generated $216M in revenue, accounting 0.27% of the company's total revenue, up 23.43% year-over-year. Imfinzi generated $4.24B in revenue, accounting 5.28% of the company's total revenue, up 52.19% year-over-year. Kanuma generated $171M in revenue, accounting 0.21% of the company's total revenue, up 6.88% year-over-year. Koselugo generated $331M in revenue, accounting 0.41% of the company's total revenue, up 59.13% year-over-year. Lokelma generated $412M in revenue, accounting 0.51% of the company's total revenue, up 42.56% year-over-year. Lynparza generated $2.81B in revenue, accounting 3.50% of the company's total revenue, up 6.56% year-over-year. Nexium generated $945M in revenue, accounting 1.18% of the company's total revenue, down -26.46% year-over-year. Oncology, Others generated $224M in revenue, accounting 0.28% of the company's total revenue, up 409.09% year-over-year. Onglyza generated $227M in revenue, accounting 0.28% of the company's total revenue, down -11.67% year-over-year. Other, Others generated $231M in revenue, accounting 0.29% of the company's total revenue, down -32.06% year-over-year. Rare Disease generated $7.76B in revenue, accounting 9.68% of the company's total revenue, up 10.08% year-over-year.
What is AstraZeneca’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of AstraZeneca was Total Oncology. This segment made a revenue of $17.14B, representing 21.37% of the company's total revenue.